Close Menu

NEW YORK – Lantern Pharma announced it will work with the National Cancer Institute's developmental therapeutics branch to identify and validate gene signatures that predict whether patients are likely to respond to treatments it is developing.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.